3Chen FP,Lee N,Wang CH,et al.Effects of hormone replacement therapy on cardiovascular risk factors postmenopausal women[J].Fertil Steril,1998,69(2):267.
4Miller J,Chan BKS,Nelson HD.Postmenopausal estrogen replacement and risk of venous thromob-embolism:a systematic evidence review and meta-analysis for the US Preventive Services Task Force[J].Ann Intern Med,2002,136:680-690.
5Rossouw JE,Anderson GL,Prentice RL,et al.Risk and benefits of estrogen plus progestin in healthy postmenopausal women[J].JAMA,2002,288:321-333.
6Haller S,Grady D,Bush T,et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.Heart and Estrogen/ Progestin Replacement Study(HERS) Research Group[J].JAMA,1998,280:605-613.
8Gambrell RD.Progestogens in estrogen-replacement therapy[J].Clin Obstet Gynecol,1995,38: 980-901.
9Beresford SAA,Weyss NS,Voigt LF,et al.Risk of endometrial cancer in relation to use ofestrogen combined with cyclic progestogen therapy in postmenopausal women[J].Lancet, 1997,349:458-461.
10Weiderpass E,Adami HO,Baron JA,et al.Risk of endometrical cancer following estrogtn replacement with and without progestins[J].J Natl Cancer Inst,1999,9(13):1131.
二级参考文献20
1[1]Chen FP, Lee N, Wang CH, et al. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women [J]. Fertil Steril,1998,69(2):267.
2[2]Lindheim SR, Presser SC, Ditkoff EC, et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the allenuating effect of added progestin [J]. Fertil Steril,1993,60(4):664.
3[3]Scarbin PY, Plu-Bureau G, Bara L, et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy [J]. Thromb Haemostas,1993,70:584-587.
4[4]Kessler C, Szymznski L, Shamsipous Z, et al. Estrogen replacement therapy and coagulation relationship to lipid lipoprotein changes [J]. Obstet Gynecol, 1997,89:329-331.
5[5]Caine GY, Baner KA, Barzeger S, et al. Coagulation activation following estrogen administration to postmenopausal women [J]. Thromb Haemostas,1992,68:392-395.
6[6]Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk of venous thrombo-embolism: a systematic evidence review and meta-analysis for the US Preventive Services Task Force [J]. Ann Intern Med,2002,136:680-690.
7[7]Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women [J].JAMA,2002,288:321-333.
8[8]Halley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group [J]. JAMA,1998,280:605-613.
9[9]Gambrell RD. Progestogens in estrogen-replacement therapy [J]. Clin Obstet Gynecol,1995,38:890-901.
10[10]Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestogen therapy in postmenopausal women [J]. Lancet,1997,349:458-461.
